215 related articles for article (PubMed ID: 29951305)
1. Oncogene-addicted non-small cell lung cancer and immunotherapy.
Tsakonas G; Ekman S
J Thorac Dis; 2018 May; 10(Suppl 13):S1547-S1555. PubMed ID: 29951305
[TBL] [Abstract][Full Text] [Related]
2. RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature.
Baglivo S; Ludovini V; Moretti R; Bellezza G; Sidoni A; Roila F; Metro G
Oncol Ther; 2020 Dec; 8(2):333-339. PubMed ID: 32700042
[TBL] [Abstract][Full Text] [Related]
3. Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions.
Schenk EL
Transl Lung Cancer Res; 2023 Feb; 12(2):322-336. PubMed ID: 36895933
[TBL] [Abstract][Full Text] [Related]
4. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.
Spagnuolo A; Muto M; Monaco F; Colantuoni G; Gridelli C
Transl Lung Cancer Res; 2019 Dec; 8(6):1134-1151. PubMed ID: 32010591
[TBL] [Abstract][Full Text] [Related]
5. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.
Pilotto S; Molina-Vila MA; Karachaliou N; Carbognin L; Viteri S; González-Cao M; Bria E; Tortora G; Rosell R
Transl Lung Cancer Res; 2015 Dec; 4(6):721-7. PubMed ID: 26798581
[TBL] [Abstract][Full Text] [Related]
6. Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer.
Listì A; Barraco N; Bono M; Insalaco L; Castellana L; Cutaia S; Ricciardi MR; Gristina V; Bronte E; Pantuso G; Passiglia F
Transl Cancer Res; 2019 Jan; 8(Suppl 1):S55-S63. PubMed ID: 35117064
[TBL] [Abstract][Full Text] [Related]
7. DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy.
Fang C; Xu D; Su J; Dry JR; Linghu B
NPJ Digit Med; 2021 Feb; 4(1):14. PubMed ID: 33531613
[TBL] [Abstract][Full Text] [Related]
8. Exploiting
Di Noia V; D'Argento E; Pilotto S; Ferrara MG; Milella M; Tortora G; Bria E
Transl Lung Cancer Res; 2018 Dec; 7(Suppl 4):S312-S317. PubMed ID: 30705843
[No Abstract] [Full Text] [Related]
9. Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.
Gridelli C; Ascierto PA; Grossi F; Baldini E; Favaretto A; Garassino MC; Morabito A; Migliorino MR; Rossi A; de Marinis F
Curr Clin Pharmacol; 2018; 13(2):76-84. PubMed ID: 29992894
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
[TBL] [Abstract][Full Text] [Related]
11. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance.
Schrank Z; Chhabra G; Lin L; Iderzorig T; Osude C; Khan N; Kuckovic A; Singh S; Miller RJ; Puri N
Cancers (Basel); 2018 Jul; 10(7):. PubMed ID: 29973561
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab for the treatment of non-small cell lung cancer.
Mezquita L; Planchard D
Expert Rev Respir Med; 2018 Aug; 12(8):627-639. PubMed ID: 29958099
[TBL] [Abstract][Full Text] [Related]
13. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.
Su S; Dong ZY; Xie Z; Yan LX; Li YF; Su J; Liu SY; Yin K; Chen RL; Huang SM; Chen ZH; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Nov; 13(11):1668-1675. PubMed ID: 30056164
[TBL] [Abstract][Full Text] [Related]
14. First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
Addeo A; Metro G
Drugs Context; 2018; 7():212537. PubMed ID: 30023004
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.
Domagała-Kulawik J
Adv Respir Med; 2018; 86(3):. PubMed ID: 29960281
[TBL] [Abstract][Full Text] [Related]
16. Vaccine and immune cell therapy in non-small cell lung cancer.
Oliveres H; Caglevic C; Passiglia F; Taverna S; Smits E; Rolfo C
J Thorac Dis; 2018 May; 10(Suppl 13):S1602-S1614. PubMed ID: 29951309
[TBL] [Abstract][Full Text] [Related]
17. Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient.
Horio Y; Takamatsu K; Tamanoi D; Sato R; Saruwatari K; Ikeda T; Nakane S; Nakajima M; Saeki S; Ichiyasu H; Fujii K; Tomita Y
Eur J Immunol; 2018 Oct; 48(10):1764-1767. PubMed ID: 29981156
[TBL] [Abstract][Full Text] [Related]
18. Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.
Califano R; Lal R; Lewanski C; Nicolson MC; Ottensmeier CH; Popat S; Hodgson M; Postmus PE
Future Oncol; 2018 Oct; 14(23):2415-2431. PubMed ID: 29978725
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor-associated acidity in cancer immunotherapy.
Lacroix R; Rozeman EA; Kreutz M; Renner K; Blank CU
Cancer Immunol Immunother; 2018 Sep; 67(9):1331-1348. PubMed ID: 29974196
[TBL] [Abstract][Full Text] [Related]
20. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Vendetti FP; Karukonda P; Clump DA; Teo T; Lalonde R; Nugent K; Ballew M; Kiesel BF; Beumer JH; Sarkar SN; Conrads TP; O'Connor MJ; Ferris RL; Tran PT; Delgoffe GM; Bakkenist CJ
J Clin Invest; 2018 Aug; 128(9):3926-3940. PubMed ID: 29952768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
